ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

Lytho, a leading provider of creative workflow solutions, is proud to announce its inclusion in G2's 2025 Best ...

ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.1 The ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

The global HIV drugs industry was valued at USD 28.6 billion in 2023 and is projected to grow at a CAGR of 4.7% from 2024 to ...

February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number ...

• In February 2025, AbbVie announced that the FDA had approved Emblaveo (aztreonam and avibactam) in combination with ...